TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
1.580
-0.050 (-3.07%)
Nov 3, 2026, 10:17 AM EST - Market open
TransCode Therapeutics Employees
TransCode Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 5 or 71.43% compared to the previous year. That makes TransCode Therapeutics the 39,858th largest employer in the world and 5,974th in the United States.
Employees
12
Change (1Y)
5
Growth (1Y)
71.43%
Revenue / Employee
n/a
Profits / Employee
-$3,857,068
Market Cap
26.75M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 12 | 5 | 71.43% | 12 | 0 |
| Dec 31, 2024 | 7 | -3 | -30.00% | 7 | 0 |
| Sep 30, 2024 | 8 | -2 | -20.00% | 8 | 0 |
| Dec 31, 2023 | 10 | -9 | -47.37% | 10 | 0 |
| Dec 31, 2022 | 19 | 10 | 111.11% | 19 | 0 |
| Dec 31, 2021 | 9 | 3 | 50.00% | 8 | 1 |
| Sep 30, 2021 | 7 | 1 | 16.67% | 7 | 0 |
| Jun 30, 2021 | 6 | 0 | - | 2 | 4 |
| Mar 31, 2021 | 6 | 0 | - | 2 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| Metagenomi Therapeutics | 113 |
| Aligos Therapeutics | 82 |
| BeyondSpring | 44 |
| NextCure | 40 |
| Aardvark Therapeutics | 28 |
| ABVC BioPharma | 19 |
| BriaCell Therapeutics | 16 |
RNAZ News
- 5 days ago - Transcode Therapeutics begins formal strategic process to evaluate opportunities - TheFly
- 5 days ago - TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio - PRNewsWire
- 8 days ago - Transcode Therapeutics presents Phase 1a clinical data for TTX-MC138 in tumors - TheFly
- 8 days ago - TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026 - PRNewsWire
- 15 days ago - TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026 - PRNewsWire
- 21 days ago - Natera, Transcode to collaborate on Phase 2a trial of TTX-MC138 - TheFly
- 21 days ago - Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer - Business Wire
- 4 weeks ago - TransCode Therapeutics Slides: Investor presentation - Filings